3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis

Movement Disorders

Volumn 28, Issue 12, 2013, Pages 1653-1660

  Lewitt, Peter A ^a,b   Li, Jia ^c   Lu, Mei ^c   Beach, Thomas G ^d   Adler, Charles H ^e   Guo, Lining ^f  

^a HENRY FORD HOSPITAL   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d SUN HEALTH RESEARCH INSTITUTE   (United States)

^e MAYO CLINIC   (United States)

^f METABOLON INC   (United States)

Author keywords

Biomarker; Cerebrospinal fluid; Metabolomics; Parkinson's disease

Indexed keywords

3 HYDROXYKYNURENINE; BIOLOGICAL MARKER;

ACETYLATION; ADULT; AGED; ARTICLE; CEREBROSPINAL FLUID; EXCITOTOXICITY; FEMALE; GAS CHROMATOGRAPHY; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METABOLOMICS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SUPPORT VECTOR MACHINE;

BIOMARKER; CEREBROSPINAL FLUID; METABOLOMICS; PARKINSON'S DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; GLUTATHIONE; HUMANS; KYNURENINE; MALE; MASS SPECTROMETRY; METABOLOMICS; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SENSITIVITY AND SPECIFICITY;

EID: 84886413067     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25555     Document Type: Article

References (41)

1. LeWitt PA, Galloway MP. Neurochemical markers of Parkinson's disease. In: Koller WC, Paulson G, eds. Therapy of Parkinson's Disease. New York: Marcel Dekker; 1990:63-93.
2. Antoniades CA, Barker RA. The search for biomarkers in Parkinson's disease: a critical review. Expert Rev Neurother 2008;8:1841-1852.
3. Caudle WM, Bammler TK, Lin Y, et al. Using "omics" to define pathogenesis and biomarkers of Parkinson's disease. Expert Rev Neurother 2010;10:925-942.
4. van Dijk KD, Teunissen CE, Drukarch B, et al. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. Neurobiol Dis 2010;39:229-241.
5. Nyhlen J, Constantinescu R, Zetterberg H. Problems associated with fluid biomarkers for Parkinson's disease. Biomarkers Med 2010;4:671-681.
6. Gerlach M, Maetzler W, Broich K, et al. Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeutics. J Neural Transm 2012;119:39-52.
7. LeWitt PA, Huber BR, Zhang J. An update on CSF biomarkers of Parkinson's disease. In: Mandel S, ed. Neurodegenerative Diseases: Integrative PPPM Approach as the Medicine of the Future. Advances in Predictive, Preventive, and Personalized Medicine. vol 2. Dordrecht: Springer; 2013:161-184.
8. LeWitt P, Galloway M, Matson W, et al. Markers of dopamine metabolism in Parkinson's disease. Neurology 1992;42:2111-2117.
9. Parkinson Study Group. CSF homovanillic acid in the DATATOP study on Parkinson's disease. Arch Neurol 1995;52:237-245.
10. Goldstein DS, Holmes C, Sharabi Y. Cerebrospinal fluid biomarkers of central catecholamine deficiency in Parkinson's disease and other synucleinopathies. Brain 2012;135:1900-1913.
11. Shi M, Bradner J, Hancock AM, et al. Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011;69:570-580.
12. Lawton KA, Berger A, Mitchell M, et al. Analysis of the adult human plasma metabolome. Pharmacogenomics 2008;9:383-397.
13. Kaddurah-Daouk R, Krishnan KRR. Metabolomics: a global biochemical approach to the study of central nervous system disease. Neuropsychopharmacology 2009;34:173-186.
14. Evans AM, DeHaven CD, Barrett T, et al. Integrated, nontargeted ultrahigh performance liquid chromatography/electrospray ionization tandem mass spectrometry platform for the identification and relative quantification of the small-molecule complement of biological systems. Anal Chem 2009;81:6656-6667.
15. Schapira AH. Targeting mitochondria for neuroprotection in Parkinson's disease. Antioxid Redox Signal 2012;16:965-973.
16. Ogawa T, Matson WR, Beal MF, et al. Kynurenine pathway abnormalities in Parkinson's disease. Neurology 1992;42:1702-1706.
17. Zinger A, Barcia C, Herrero MT, Guillemin GJ. The involvement of neuroinflammation and kynurenine pathway in Parkinson's disease. Parkinsons Dis 2011;2011:716859.
18. Beach TG, Sue LI, Walker DG, et al. The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Banking 2008;9:229-245.
19. Maarouf CL, Beach TG, Adler CH, et al. Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res 2012;34:669-676.
20. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 1997;18(4 Suppl):S1-S2.
21. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement 2012;8:1-13.
22. Ohta T, Masutomi N, Tsutsui N, et al. Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats. Toxicol Pathol 2009;37:521-535.
23. DeHaven CD, Evans AM, Dai H, Lawton KA. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. J Cheminform 2010;2:9.
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 1995;57:289-300.
25. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-1061.
26. Feng Z, Prentice R, Srivastava S. Research issues and strategies for genomic and proteomic biomarker discovery and validation: a statistical perspective. Pharmacogenomics 2004;5:709-719.
27. Lee JW, Lee JB, Park M, Song SH. An extensive comparison of recent classification tools applied to microarray data. Comput Stat Data Anal 2005;48:869-885.
28. Mahadevan S, Shah SL, Marrie TJ, Slupsky CM. Analysis of metabolomic data using support vector machines. Anal Chem. 2008;80:7562-7570.
29. Xia J, Wishart DS. Web-based inference of biological patterns, functions and pathways from metabolomic data using MetaboAnalyst. Nat Protoc 2011;6:743-760.
30. Szabó N, Kincses ZT, Toldi J, Vécsei L. Altered tryptophan metabolism in Parkinson's disease: a possible novel therapeutic approach. J Neurol Sci 2011;310:256-260.
31. Schwarcz R, Bruno JP, Muchowski PJ, Wu H-Q. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev 2012;13:465-477.
32. Maetzler W, Schmid SP, Wurster I, et al. Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases. Mov Disord 2011;26:176-181.
33. Schapira AH, Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov Disord 2011;26:1049-1055.
34. Trexler AJ, Rhoades E. N-Terminal acetylation is critical for forming α-helical oligomer of α-synuclein. Protein Sci 2012;21:601-605.
35. Zhou Y, Holmseth S, Hua R, et al. The betaine-GABA transporter (BGT1, slc6a12) is predominantly expressed in the liver and at lower levels in the kidneys and at the brain surface. Am J Physiol Renal Physiol 2012;302:F316-F328.
36. Alirezaei M, Jelodar G, Niknam P, et al. Betaine prevents ethanol-induced oxidative stress and reduces total homocysteine in the rat cerebellum. J Physiol Biochem 2011;67:605-612.
37. Ros-Bernal F, Hunot S, Herrero MT, et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci U S A 2011;108:6632-6637.
38. Roher AE, Maarouf CL, Sue LI, et al. Proteomics-derived cerebrospinal fluid markers of autopsy-confirmed Alzheimer's disease. Biomarkers 2009;14:493-501.
39. Bogdanov M, Matson WR, Wang L, et al. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 2008;131:389-396.
40. Michell AW, Mosedale D, Grainger DJ, Barker RA. Metabolomic analysis of urine and serum in Parkinson's disease. Metabolomics 2008;4:191-201.
41. Johansen KK, Wang L, Aasly JO, et al. Metabolomic profiling in LRRK2-related Parkinson's disease. PLoS One 2009;4:e7551.